Despite these limitations, TDM-guided dosing (1 mg/L–5.5 mg/L) remains advised for high-risk subgroups (e.g., cirrhosis, CYP2C19 poor metabolizers) to mitigate hepatotoxicity risk documented in prospective studies. The gene discussed is CYP2C19; the disease is Cirrhosis.